Antivirals for Herpes Simplex Virus

Antivirals for Herpes Simplex Virus

Antivirals for Herpes Simplex Virus Goal(s): Cover oral and/or topical antivirals only for covered diagnoses. HSV infections are covered only when complicated by an immunocompromised host. Length of Authorization: Up to 12 months (criteria specific) Requires PA: Non-preferred drugs Covered Alternatives: Current PMPDP preferred drug list per OAR 410-121-0030 at www.orpdl.org Searchable site for Oregon FFS Drug Class listed at www.orpdl.org/drugs/ Approval Criteria 1. What diagnosis is being treated? Record ICD10 code 2. Will the prescriber consider a change to a Yes: Inform prescriber No: Go to #3 preferred product? of covered alternatives in class. Message: Preferred products do not require a PA. Preferred products are evidence-based reviewed for comparative effectiveness and safety by the Oregon Pharmacy & Therapeutics Committee. 3. Is the diagnosis uncomplicated herpes Yes: Go to #4 No: Go to #6 simplex virus infection? 4. Pass to RPh: Is the patient Yes: Approve for up to No: Go to #5 immunocompromised (document ICD10 12 months code). Examples: Diagnosis of cancer AND currently undergoing chemotherapy or radiation. Document therapy and length of treatment. Solid organ transplant HIV/AIDS Approval Criteria 5. Is the patient currently taking an Yes: Approve for up to No: Pass to RPh. Go to immunosuppressive drug? 90 days #6. Document name of drug. If is drug not in the list below, pass to RPh for evaluation. Immunosuppressive drugs include, but are not limited to: Immunosuppressants Abatacept Infliximab Adalimumab Leflunomide Anakinra Methotrexate Apremilast Natalizumab Azathioprine Rituximab Basiliximab Secukinumab Certolizumab pegol Sirolimus Cyclosporine Tacrolimus Cyclosporine Tocilizumab Etanercept Tofacitinib Golimumab Ustekinumab Hydroxychloroquine Vedolizumab 6. RPh only: If funded and clinic If non-funded, deny All other indications need to be evaluated provides supporting (not funded by the as to whether they are an OHP-funded literature, approve for OHP). condition. length of treatment. If length of treatment is Note: Deny viral ICD- not provided, approve 10 codes that do not for 3 months. appear on the OHP funding list pending a Note: deny non-viral more specific diagnosis diagnoses (medical code (not funded by the appropriateness) OHP). P&T Review: 9/19 (KS), 7/16 (KS); 1/14; 1/12; 9/10 (KS) Implementation: 8/16; 1/1/11 .

View Full Text

Details

  • File Type
    pdf
  • Upload Time
    -
  • Content Languages
    English
  • Upload User
    Anonymous/Not logged-in
  • File Pages
    2 Page
  • File Size
    -

Download

Channel Download Status
Express Download Enable

Copyright

We respect the copyrights and intellectual property rights of all users. All uploaded documents are either original works of the uploader or authorized works of the rightful owners.

  • Not to be reproduced or distributed without explicit permission.
  • Not used for commercial purposes outside of approved use cases.
  • Not used to infringe on the rights of the original creators.
  • If you believe any content infringes your copyright, please contact us immediately.

Support

For help with questions, suggestions, or problems, please contact us